Banaba leaves (Lagerstroemia speciosa LINN.) have been used as a traditional medicine in Southeast Asia, and tea made from the leaves is used as a treatment for diabetes. The leaves contain large amounts of corosolic acid (CRA) (Fig.  1) , which recently has attracted attention for its biological properties. [1] [2] [3] [4] [5] [6] [7] It was shown that Banaba leaf extract (1% CRA) treatment for 2 weeks decreased blood glucose levels in humans. 8) In addition, CRA (10 mg) has been shown to reduce post challenge plasma glucose levels at 90 min in humans. 7) We previously reported that CRA ameliorates hypertension and abnormal lipid metabolism as well as mitigating oxidative stress and the inflammatory state in SHR/NDmcrcp rats on a high fat diet, 9) that is an animal model of metabolic syndrome.
Banaba leaves (Lagerstroemia speciosa LINN.) have been used as a traditional medicine in Southeast Asia, and tea made from the leaves is used as a treatment for diabetes. The leaves contain large amounts of corosolic acid (CRA) (Fig.  1) , which recently has attracted attention for its biological properties. [1] [2] [3] [4] [5] [6] [7] It was shown that Banaba leaf extract (1% CRA) treatment for 2 weeks decreased blood glucose levels in humans. 8) In addition, CRA (10 mg) has been shown to reduce post challenge plasma glucose levels at 90 min in humans. 7) We previously reported that CRA ameliorates hypertension and abnormal lipid metabolism as well as mitigating oxidative stress and the inflammatory state in SHR/NDmcrcp rats on a high fat diet, 9) that is an animal model of metabolic syndrome. 10) We also found that the administration of CRA (10 mg/kg) in a normal diet for 2 weeks improved hyperglycemia by reducing insulin resistance in a KK-Ay mouse, an obese animal model that spontaneously develops hypertriglyceridemia, hyperglycemia, hyperinsulinemia, and diabetes. 11, 12) However, the effects of CRA on the adipocytokines and transcription factors that play central roles in the development of obesity are unknown.
Obesity and type 2 diabetes in both humans and animals are associated with insulin resistance. 13) Adiponectin is an insulin-sensitizing hormone, and plasma levels of adiponectin have been reported to be significantly reduced in obese /diabetic mice and humans. [14] [15] [16] It also was reported that adiponectin receptors, AdipoR1 and AdipoR2, are downregulated in adipose tissue and skeletal muscle in obese diabetic ob/ob mouse, which is correlated with decreased adiponectin sensitivity. 17) Abnormalities of lipid metabolism are frequently observed in obesity and type 2 diabetes. Peroxisome proliferator-activated receptor (PPAR)a is predominantly expressed in liver, and regulates the expression of genes involved in lipid metabolism. Activators of PPARa decrease circulating lipid levels and are commonly used to treat hypertriglyceridemia and other dyslipidemic states. Recent studies suggest that the activation of PPARa prevents high fat diet-induced obesity, 18) insulin resistance, 18, 19) and hepatic steatosis. 20) It was also found that activation of PPARa increased AdipoR1 and AdipoR2 expression in adipocytes in vivo. 21) Growth and differentiation of adipocytes are regulated by PPARg, which is highly expressed in adipose tissue. Activation of PPARg by agonists such as thiazolidinediones increases the number of small adipocytes, which increases the amount of the insulin-sensitizing hormone adiponectin. 15, 22) PPARg activation also stimulates lipid storage in adipocytes and reduces lipotoxicity in liver and skeletal muscle, thereby improving insulin sensitivity. 23) In the present study, we examined the inhibitory effects of CRA on the development of obesity and hepatic steatosis in KK-Ay mice using 43 mg/kg CRA, a dosage similar to that used in the previous study. 11 ) We performed biochemical measurements, body composition analysis, and morphological analysis of liver and white adipose tissue (WAT). In addition, we examined gene and protein expression of PPARa in liver, which regulates b-oxidation of fatty acid. We also examined gene expression of AdipoR1 and AdipoR2, which are increased by PPARa agonist, and PPARa, which increases adiponectin, in WAT.
MATERIALS AND METHODS
Chemicals CRA provided by Use Techno Corporation (Kyoto, Japan) was stored at room temperature until use. All other chemicals were of reagent grade.
Animals Male KK-Ay mice were purchased from Clea Japan (Tokyo, Japan). The mice were housed in an air-controlled room (temperature 25Ϯ2°C and 50% humidity) with a 12 h light/dark-cycle and food and water provided ad libitum. Six-week-old male KK-Ay mice (1 mouse/cage) were fed a high fat diet with (CRA-treated mice) or without (control mice) 0.023% (w/w) CRA for 9 weeks. The high fat diet contained 45% kcal as fat, 35% kcal as carbohydrate, and 20% kcal as protein, with an energy density of 3.57 kcal/g. 24) All studies were performed in the laboratories of the Department of Diabetes and Clinical Nutrition, Kyoto University, in accordance with the Declaration of Helsinki. The Animal Care Committee of Kyoto University Graduate School of Medicine approved animal care and procedures.
Computed Tomography (CT)-Based Body Composition Analysis CT-based analysis of body composition was performed after 9 weeks. The mice were anesthetized with intraperitoneal injections of pentobarbital sodium, and scanned using a LaTheta (LCT-100M) experimental animal CT system (Aloka, Tokyo, Japan). Contiguous 1 mm slice images of the whole abdominal cavity (Fig. 3A) were used for quantitative assessment by LaTheta software (version 1.00), as described previously. 25) Visceral plus subcutaneous fat mass (total fat mass) and lean body mass were evaluated quantitatively.
Histological Examination Epididymal white adipose tissue (WAT) after 9 weeks was removed and fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin.
26) The diameter of the adipocytes was determined by microsocope (BZ-8000, Keyence, Osaka, Japan); 50 cells per mouse were measured in several parts of the epididymal fat pad. Liver was fixed in 4% paraformaldehyde in 0.1 M phosphate-buffered saline for 2 h at 4°C, frozen, sectioned, stained with Oil Red O, and counterstained with hematoxylin.
27)

Measurement of Liver Triglyceride (TG) Content
To analyze hepatic TG levels, approximately 0.2 g of tissue was homogenized and extracted in a chloroform : methanol mixture (2 : 1 v/v). 28) Triglyceride was enzymatically quantified using a TG E Test Wako (Wako Pure Chemical Industries, Osaka, Japan).
Biochemical Measurements Blood samples were collected in heparinized capillary tubes and centrifuged at 2400 g. Plasma TG and glucose levels were measured using a TG E test and Glucose II test, respectively (Wako Pure Chemical Industries, Osaka, Japan). Plasma insulin levels were measured using a mouse insulin ELISA kit (Shibayagi, Gunma, Japan). Plasma adiponectin levels were measured by mouse/ rat adiponectin immunoassay kit (Otsuka Pharmaceutical, Tokushima, Japan).
Quantitaive Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Total RNA was isolated from liver and fat with Trizol reagent (Invitrogen, CA, U.S.A.), and examined by real time quantitative RT-PCR using a PE Applied Biosystems prism model 7000 sequence detection instrument. SYBER Green PCR Master Mix (Applied Biosystem, CA, U.S.A.) was prepared for the PCR run. Thermal cycling conditions were denaturation at 95°C for 10 min followed by 50 cycles at 95°C for 15 s and 60°C for 1 min. The sequences of the sense and antisence primers of PPARa, PPARg, AdipoR1 and AdipoR2 used for amplication from mouse liver and WAT were as follows: the sense primer for PPARa was ccctgaacatcgagtgtcgaa, the antisence primer ttgcagctccgatcacactt; the sense primer for PPARa was tgtcggtttcagaagtgcctt, the antisense primer gctcgcagatcagcagactct; the sense primer for AdipoR1 was 5Ј-acgttggagagtcatcccgtat-3Ј, the antisense primer 5Ј-ctctgtgtggatgcggaagat-3Ј; the sense primer for AdipoR2 was 5Ј-tcccaggaagatgaagggtttat-3Ј, the antisence primer 5Ј-ttccattcgttcgatagcatga-3Ј. Gene expression levels were corrected for GAPDH mRNA level.
Protein Analysis For PPARa analysis, nuclear extracts were prepared essentially as described by Gebel et al. 29) Briefly, frozen liver samples (0.1 g) were homogenized in 0.5 ml of ice cold buffer containing 20 mM Tris-HCl (pH 7.4), 10% glycerol, 1 mM EDTA, 25 mM KCl, and 1 mM dithiothreitol together with protease inhibitors (Complete, EDTA Free; Roche, Mannheim, Germany), and the nuclei were then pelleted and resuspended in fresh buffer 0.4 M NaCl. The suspensions were mixed (4°C, 30 min) and centrifuged (2000ϫg, 4°C, 30 min), and supernatants (nuclear extracts) were collected. Protein was analyzed using a kit from BioRad Laboratories (CA, U.S.A.) with bovine serum albumin as standard.
Nuclear Extracts (15 mg protein) were 12% SDS-polyacrylamide gels, transferred to PVDF membranes, which were blocked in TBST buffer (20 mM Tris-HCl [pH 7.5] and 55 mM NaCl, 0.1% Tween 20) containing 5% non-fat milk powder and incubated with primary antibody 24 h. Primary antibodies and dilutions used were as follows: mouse anti-GAPDH (1 : 5000, Chemicon, CA, U.S.A.), rabbit antimurine PPARa (1 : 500, Santa Cruz Biothechnology, SantaCruz, CA, U.S.A.). TBST was used as wash buffer and antibody diluent. After washing for 3ϫ10 min, blots were incubated (60 min) with horseradish peroxidase-conjugated secondary anti-bodies, either anti-rabbit IgG (1 : 5000, GE Healthcare, Buckinghamshire, U.K.) or anti-mouse IgG (1 : 5000, GE Healthcare, Buckinghamshire, U.K.). Blots were given final washes (2ϫ15 min) and antibody binding was detected on X-ray film by enhanced chemiluminescenece (ECL Advance, GE Healthcare, Buckinghamshire, U.K.).
Statistics Results are expressed as meanϮS.E.M. Statistical analysis was performed using unpaired Student's t-test for data from control and CRA-treated mice. Difference was considered significant at pϽ0.05.
RESULTS
Effects of CRA on Body Weight and Fat Mass in KK-
Ay Mice KK-Ay mice were fed a high fat diet with (CRAtreated mice) or without (control mice) 0.023 % (w/w) CRA for 9 weeks. As shown in Fig. 2 , mice treated with CRA for 9 weeks had 10% less body weight than control mice. In normal diet-fed mice, there were no significant differences in CRA-treated or control mice (data not shown). There were no significant differences in food intake between CRAtreated (460Ϯ10 g/9 weeks) and control mice (454Ϯ8 g/9 weeks). As shown in Fig. 3 , a significant decrease in total fat mass (Fig. 3B, 15% , pϽ0.05) and visceral fat mass (Fig. 3D,  16% , pϽ0.05) was observed in CRA-treated mice compared to controls. Subcutaneous fat mass was somewhat decreased, but not significantly, in the CRA-treated mice (Fig. 3C, 14% , pϽ0.09). Lean body mass was similar in control and CRAtreated mice (Fig. 3E) .
Effects of CRA on Fasting Plasma Glucose, Insulin, TG and Fed Plasma Adiponectin Levels As shown in Fig. 4 , the CRA-treated mice showed levels of fasting plasma glucose (A) and insulin (B) reduced by 23% (pϽ0.05) and 41% (pϽ0.05), respectively, compared to controls, suggesting that the CRA-treated mice were more insulin sensitive. CRAtreated mice showed fasting plasma TG (Fig. 4C ) levels reduced by 22% (pϽ0.05) compared to controls. Fed plasma levels of adiponectin were higher (16%, pϽ0.05) in CRAtreated mice compared to controls (Fig. 4D) .
Histology of Epididymal WAT and Effects of CRA on WAT mRNA Expression Levels of AdipoR1, AdipoR2 and PPARg g Figure 5A shows representative sections of epididymal WAT from control and mice treated with CRA for 9 weeks, stained with hematoxylin and eosin. As shown in Fig.  5B , the size of adipocytes of epididymal WAT of CRAtreated mice was significantly less (28%, pϽ0.05) than that of controls. AdipoR1 mRNA expression levels were significantly higher in CRA-treated mice (15%, pϽ0.05) than in controls (Fig. 5C ), although there was no difference in AdipoR2 mRNA between control and CRA-treated mice (Fig.  5D) . CRA-treated mice showed significantly elevated PPARg mRNA expression levels (60%, pϽ0.05) compared to controls (Fig. 5E) .
Histology of Liver, Liver TG Content, and Hepatic mRNA and Protein Expression of PPARa a Figure 6A shows Oil Red O-stained sections of liver of control mice and CRA-treated mice. The liver of control mice showed widespread deposition of fat globules of various sizes. In contrast, the liver of CRA-treated mice showed less fat accumulation, indicating less hepatic steatosis than in controls. The liver weight of CRA-treated mice was significantly less (35%, pϽ0.05) than in controls (Fig. 6B) , which is associated with the significantly decreased hepatic TG accumulation in CRA-treated mice (37%, pϽ0.05) (Fig. 6C) . Since PPARa plays an important role in maintaining homeostasis of lipid metabolism, PPARa mRNA expression was examined in liver samples from controls and mice treated with CRA for 9 weeks. As shown in Fig. 6D , expression of PPARa mRNA in CRA-treated mice was significantly higher (64%, pϽ0.05) than in controls. We also confirmed protein expression of PPARa and found that CRA-treated mice showed significantly higher (31%, pϽ0.05) PPARa protein levels than in controls (Fig. 6E) .
DISCUSSION
This is the first study to show that CRA treatment in mice fed a high fat diet contributes to reduced body weight and hepatic steatosis associated with increased expression of PPARa in liver and PPARg in WAT. CRA treatment also may improve insulin sensitivity by increasing plasma adiponectin and WAT AdipoR1 levels.
In the present study, we found that CRA increased mRNA and protein expression of PPARa in liver, suggesting that CRA may act as a PPARa agonist. The decreased body weight and fat mass observed in the CRA-treated mice are most likely due to increased b-oxidation and energy expenditure by PPARa activation, as seen in mice treated with PPARa agonists. 18, 19, 30, 31) Hypertriglycemia and hepatic steatosis are also ameliorated by CRA treatment, in a manner similar to that by PPARa agonists, 20) by increasing fatty acid b-oxidation in liver. CRA-treated mice on a high fat diet showed significantly reduced liver weight compared to controls, due to the significantly decreased hepatic TG accumulation. However, there are several reports of increased liver weight by synthetic PPARa agonists in rodents on a normal diet [32] [33] [34] through induction of DNA synthesis and suppression of apoptosis in hepatocytes. 35) In the present study, increased AdipoR1 expression in WAT was found in the CRAtreated mice, which may well contribute partly to the CRArelated improvement in insulin sensitivity.
In addition, CRA treatment was found in the present study to increase PPARg expression in WAT. Treatment of obese diabetic mice with thiazolidinediones, a PPARg agonist, has been suggested to stimulate adipocyte differentiation and apoptosis, thereby preventing adipocyte hypertrophy, 23, 36) which is consistent with our results. Increased plasma adiponectin levels also play an essential role in improved insulin sensitivity in CRA-treated mice, most likely due to increased number of small adipocytes through CRA-induced activation of PPARg in WAT, resulting in decreased plasma glucose levels. It is noteworthy that CRA can activate both PPARa and PPARg. Tsuchida et al. reported that activation of PPARa and PPARg by combination therapy of Wy-14643 and rosiglitazone improved insulin sensitivity and reduced body weight in KK-Ay mice. 21) Compounds that have dual agonistic activity on both of these receptors have been shown to exhibit several beneficial metabolic effects in obese diabetic animals. Ragaglitazar, a PPARa and PPARg agonist, was shown to reduce plasma TG and glucose levels in high fat diet-fed animals in the absence of weight gain, 32) and similar results were obtained in Zucker fa/fa rats. 37) CRA may therefore have therapeutic potential as a dual agonist of PPARa and PPARg.
In conclusion, we have demonstrated that CRA ameliorates high fat diet-induced obesity and hepatic steatosis in genetically obese KK-Ay mice, at least in part, by increasing PPARa expression in liver and PPARg expression in WAT. CRA treatment also improved insulin sensitivity by increasing plasma adiponectin levels and WAT AdipoR1 levels. As obese patients are likely to prefer a high fat diet, CRA may be an effective therapeutic option for the treatment of obesity and diabetes.
